Alkem Laboratories Limited has received a GST demand order from statutory authorities totaling ₹56.71 crores for the financial year 2018-19. The pharmaceutical company disclosed this development on December 30, 2025, in compliance with SEBI LODR Regulations.

GST Demand Order Details

The order was issued by the Assistant Commissioner, Ward 203, Zone 11, Delhi, and received by the company on December 29, 2025. The demand pertains to the company's Delhi GSTIN for FY2018-19.

Nature of Alleged Violation

The demand order primarily alleges excess availment of Input Tax Credit under the applicable provisions of the Central Goods and Services Tax (CGST) Act, 2017 and State Goods and Services Tax (SGST) Act, 2017. The company has clearly stated its disagreement with the allegations made in the demand order.

Company's Response and Next Steps

Alkem Laboratories has indicated that it is in the process of taking appropriate action against the order, including filing an appeal. The company maintains that it does not agree with the demand order and will contest the same through proper legal channels.

Impact Assessment

According to the company's disclosure, there is no material impact on the financial, operational, or other activities of Alkem Laboratories due to this GST demand order. The company has made this information available on its website at www.alkemlabs.com for stakeholder reference.

The disclosure was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer, ensuring proper compliance with regulatory requirements under SEBI LODR Regulations.

Alkem Laboratories Limited has received two GST demand orders from statutory authorities totaling ₹1.89 crores, including penalties, for alleged excess availment of Input Tax Credit across different financial years. The pharmaceutical company plans to contest both orders.

GST Demand Orders Overview

The company received orders from two separate tax jurisdictions. The details of both orders are presented below:

Nature of Alleged Violations

Both demand orders primarily allege excess availment of Input Tax Credit (ITC) by the company during the respective financial years. The orders have been issued under the applicable provisions of the Integrated Goods and Services Tax Act, 2017, with interest charges also being levied as per statutory requirements.

The Haryana order represents the more significant demand, accounting for approximately 94% of the total GST amount sought by the authorities. This order pertains to the financial year 2021-22, while the Rajasthan order relates to FY 2018-19.

Company's Response and Legal Action

Alkem Laboratories has stated that it does not agree with either of the demand orders and plans to contest both through appropriate legal channels. The company is in the process of taking necessary action, including filing appeals against the orders with higher tax authorities.

The pharmaceutical company has emphasized that these GST orders will not have any material impact on its financial, operational, or other business activities. This assessment suggests that the company views the demands as contestable and expects favorable outcomes through the appellate process.

Regulatory Compliance

The disclosure was made in compliance with SEBI listing regulations. The information has also been made available on the company's official website at www.alkemlabs.com for stakeholder reference.